Biologist provides perspectives on new MSC frailty study published in Cell Stem Cell from Longeveron and provides background.

Osteoarthritis and osteoporosis, two common degenerative musculoskeletal diseases affecting roughly 33 million adults in the United States, leave millions coping with fragile bones, fractures, and wor...

Glucocorticoid (GC) induced osteoporosis (GIOP) remains a significant clinical problem. Here, the authors find that GCs disrupt skeletal stem cell–endothelial crosstalk via Basigin that can be targete...

Ambrosi and colleagues profile human skeletal stem cells (hSSCs) across ten fetal skeletal sites and from patients throughout adulthood, identifying, mapping, and functionally testing four distinct hS...

Abstract. In our aging society, the degeneration of the musculoskeletal system and adjacent tissues is a growing orthopedic concern. As bones age, they bec

Glucocorticoid (GC) induced osteoporosis (GIOP) and osteonecrosis remain a significant health issue with few approved therapies that can treat the bone loss and dysfunction of skeletal vasculature. Th...

Nature Reviews Endocrinology - Established antiresorptive treatments for osteoporosis only slow down bone loss, and available osteoanabolic therapies — although more effective — have...

A brain-derived hormone, CCN3, is newly identified to have a role as an osteoanabolic factor to build bone in lactating females and in the viability of offspring.